SMA Treatment Market to Exhibit at a CAGR of 28.9% by 2026; FDA Approval for Zolgensma to Spur Sales Opportunities

The spinal muscular atrophy (SMA) treatment market size is expected to reach USD 14.49 billion by 2026. The increasing incidence of spinal muscular atrophy will fuel demand for spinal muscular atrophy (SMA) treatment, which in turn will boost the spinal muscular atrophy (SMA) treatment market revenue, mentioned in a report titled “Spinal Muscular Atrophy (SMA) Treatment Market Size, Share and Industry Analysis  By Product (Nusinersen and Onasemnogen Abeparvovec), By Disease Type (Type 1 SMA, Type 2 SMA and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Geography  Forecast, 2029 - 2026” the market size stood at USD 1.72 billion in 2018 and is likely to exhibit a remarkable CAGR of 28.9%.

FDA Approval for Zolgensma to Support Market Expansion

AveXis, a biotechnology company that develops treatments for rare neurological genetic disorders launched Zolgensma after receiving approval from the US Food and Drug Administration (FDA). The new therapy is designed to treat spinal muscular atrophy (SMA) with bi-allelic mutations of survival motor neuron 1 (SMN1) gene in pediatric patients with less than 2 years of age. Zolgensma is created with an aim to the magistrate the genetic root cause of SMA by offering a functional copy of the human SMN gene by terminating the disease progression through sustained SMN protein expression with a single, one-time intravenous (IV) infusion. The launch of Zolgensma will accelerate sales opportunities for the market in the forthcoming years due to the therapy being the first and only gene therapy to get approval from the FDA for the treatment of SMA, including those who are pre-symptomatic at diagnosis. Moreover, the increasing R&D for the development of novel therapies by key players will fuel the demand for SMA treatment and therefore augment the spinal muscular atrophy (SMA) treatment market growth. For instance, Biogen announced the results from its 25-patient NURTURE study of Spinraza (nusinersen) in pre-symptomatic infants. The study of three years revealed all those treated were alive without the need for ventilation and were able to sit without support, and 88% had the ability to walk independently.

To Get the detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/spinal-muscular-atrophy-treatment-market-100576

Launch of Novel Therapeutics to Enhance Market Scope

The launch of numerous effective therapeutics by key players will boost the spinal muscular atrophy (SMA) treatment market trends during the forecast period. The demand for potent treatment options will impel major companies to introduce therapies, which will, in turn, enable speedy growth of the market. Furthermore, “the growing awareness regarding pre-diagnosis and treatment of SMA will spur growth opportunities for the market in the forthcoming years”, states our lead analysts at Fortune Business Insights. The government initiatives towards the improvement of healthcare infrastructure and offering novel therapies to patients’ will create imminent possibilities for the market in the foreseeable future.

Strategic Planning of Biogen and Novartis AG to Establish a Strong foothold

Biogen and Novartis AG accounted for the lion’s share in 2018 and are expected to remain steady in the market. The companies are focused on launching novel products for the treatment of spinal muscular atrophy. For instance, Spinraza (Nusinersen) by Biogen and Zolgensma (Onasemnogene abeparvovec) by Novartis are the only two products approved for the treatment of genetic disorders. Moreover, various products in the pipeline by the major companies will spur new opportunities for the market in the forthcoming years. For instance, Genentech, Inc. (F. Hoffmann-La Roche Ltd) and Astellas Pharma have key pipeline candidates in advanced stages of clinical trials.

Some of the Prominent Companies Operating in the Spinal Muscular Atrophy (SMA) Treatment Market Include:

• Biogen  


• Novartis AG


• Genentech, Inc./ F. Hoffmann-La Roche Ltd


• Astellas Pharma Inc.


• Genzyme Corporation


• Others

Further Reports Findings:

• Regional Analysis: The market in North America generated a revenue of USD 854 million in 2018 and is likely to grow rapidly during the forecast period owing to the presence of key awareness in the region. Europe is expected to account for a high share in the forthcoming years owing to the development of healthcare facilities in the region.


• Leading Segment: Type 1 SMA is expected to hold the largest share during the forecast period owing to the increasing prevalence of Type 1 SMA (Werdnig-Hoffmann disease).

The Spinal Muscular Atrophy (SMA) Treatment Market is Segmented into: